Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (November 2022)
28 slides from Collplant Biotechnologies's investor presentation, Nov 17, 2022
Slide 1: CollPlant Overview November 2022
CollPlant Overview November 2022
Slide 2: Safe harbor statement
Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimate
Slide 3: CollPlant – Unlocking the Regenerative Potential of rhCollagen
3 CollPlant – Unlocking the Regenerative Potential of rhCollagen Collaboration Agreements with Industry Leaders • AbbVie (ABBV) - Worldwide exclusive agreement for dermal and soft tissue fillers. Up to $103mm in payments plus royalties. • TAU and Sheba Medical Center – Co - development of a 3D biopr
Slide 4: Plant-based platform produces human collagen at mass scale
4 Expressing 5 human genes Plant - based platform produces human collagen in mass - scale
Slide 5: rhCollagen production process
Medical aesthetics BioInk Commercial products rhCollagen production process Products rhCollagen Growing Extraction Purification Transgenic tobacco Crude extract Large scale human collagen produced in tobacco plants
Slide 6: rhCollagen - The ideal building block for regenerative medicine
rhCollagen - The ideal building block for regenerative medicine 6 Animal Extracted Plant - derived Clear advantages over tissue - extracted collagen Better bio - functionality Superior homogeneity Improved safety and greater purity Cell binding domains
Slide 7: Product Pipeline
Product Pipeline Aesthetic medicine Regenerative medicine Dermal/soft tissue fillers BioInk formulations Photocurable dermal filler Soft and hard tissues Collaboration with 3D bioprinted products Breast implants Regenerative Tissue Matrix for breast reconstruction Tissue Models Gut - on - a - chip P
Slide 8: Dermal/Soft Tissue Fillers
Dermal/Soft Tissue Fillers In collaboration with
Slide 9: Dermal fillers market overview
Dermal fillers market overview ~2.6 M HA procedures in 2020 in the US 1 $5B, 9.6% CAGR Global dermal filler market, 2021, CAGR 2022 - 2028 2 $100 - $250/unit Cost per syringe 3 9 1. 2. 3. https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic - surgery - statistics - full - report - 2
Slide 10: Collaboration agreement with AbbVie
10 Collaboration agreement with AbbVie Agreement highlights: A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Financial highlights: Up to $103M in potential payments, including: • $14M upfront payment • Up to $89M
Slide 11: rhCollagen-based photocurable regenerative dermal filler
rhCollagen - based photocurable regenerative dermal filler * key attributes Photocuring in - situ Tissue regeneration Good tissue retention Sculpting before curing Easy injection (30G needle) Optimized post curing stiffness Injection Sculpting *AbbVie’s Option Product http://collplant.com/products/p
Slide 12: 12
12
Slide 13: Breast Reconstruction / Augmentation
Breast Reconstruction / Augmentation
Slide 14: Breast implants market overview
Breast implants market overview Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. $2.5B Market worldwide (2021) 1 $ 5 - 10K Cost per full procedure in US 2 ~2,200,000 Brea
Slide 15: CollPlant's 3D bioprinted regenerative breast implants
15 * Pig study initiated in Q2 2022, expected to conclude in six months CollPlant’s 3D bioprinted regenerative breast implants for aesthetic and reconstructive procedures Breast scaffold bioprinting rhCollagen + ECM components Implantation and vascularization Implant degrades over time and replaced
Slide 16: Regenerative Tissue Matrix (RTM)
Provide extra coverage, direct - to - implant reconstruction and superior cosmetic results US: mostly human - sourced (93%) EU: mostly animal - sourced Used in 61% of U.S. breast reconstruction surgeries Breast reconstruction procedures using ADMS /yr (US): 60K Market potential (US) $600Mn Surgical
Slide 17: Gut-on-a-chip
Gut - on - a - chip
Slide 18: Inflammatory bowel diseases
18 Inflammatory bowl diseases There is a need for novel personalized platforms to improve therapeutic choices and patient outcome >6 Mn patients worldwide No cure Individualized treatment for each patient, some fail to respond Limited models In predicting therapeutic response, resulting in exposure
Slide 19: 3D bioprinted gut-on-a-chip for drug discovery and personalized medicine
19 Patient specific cells to enable screening of multiple drugs and identification of the most effective personalized therapeutic response Agreement terms (Nov 2022) CollPlant receives exclusive license for development, manufacturing and commercializing of the product Tel Aviv University and Sheba w
Slide 20: 3D Bioprinted Tissues and Organs
3D Bioprinted Tissues and Organs
Slide 21: 3D bioprinting represents a wide range of development opportunities
21 In - house Development Collaboration with tier - 1 Development cost Time to market Tissues ● Breast ● Heart valve ● Cornea ● Skin ● Cartilage Endocrine glands ● Ovary ● Pancreas ● Thyroid Organs ● Lungs ● Kidney ● Liver ● Heart Scaffolds ● Spine fusion ● Tendons, ligaments ● Bones ● Nerve conduit
Slide 22: rhCollagen-based BioInks enable high resolution printing of elastic scaffolds
rhCollagen - based BioInks enable high resolution printing of elastic scaffolds
Slide 23: rhCollagen BioInk compositions in development
rhCollagen BioInk compositions in development Direct Ink Writing (DIW) Inkjet Projection Stereolithography Laser Induced Forward Transfer (LIFT) Polymers (physical properties) Ceramics (hard tissue) Nanoparticles (sustained release/ physical properties ( ECM components (biological/ physical properti
Slide 24: Collink.3D – rhCollagen bioink platform for biofabrication
24 24 24 Supports high viability of different cell types Animal - free, excellent safety profile Optimal rheology at room temperature Biocompatible, non immunogenic Collink.3D – rhCollagen - bioink platform for biofabrication Coming soon: In the market:
Slide 25: Our Partners
Our Partners Development and commercialization agreement Joint development agreement Universal BioInk Industry committee Scalable manufacturing of tissue engineered products 25 Collaboration agreement Supply agreement Joint Development Agreement
Slide 26: Experienced management team
Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida E&Y Ilana Belzer, PhD COO BioHarvest Procognia Ltd. Omrix Biopharmaceuticals Interpharm Michal Roytman VP Sales & Marketing Ocon
Slide 27: CollPlant investment thesis
CollPlant investment thesis Only commercially viable technology currently available that can produce truly human collagen Multi - billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/scaffo
Slide 28: Thank you
Thank you
CollPlant Biotechnologies — Investor Presentation (November 2022) on 6ix